EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Cyteir Therapeutics's Enterprise Value is $-20.87 Mil.
Cyteir Therapeutics's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was $-38.25 Mil. Therefore, Cyteir Therapeutics's EV-to-EBIT for today is 0.55.
The historical rank and industry rank for Cyteir Therapeutics's EV-to-EBIT or its related term are showing as below:
CYTT'
s EV-to-EBIT Range Over the Past 10 Years
Min: -6432.96 Med: 0 Max: 563.76
Current: 0.55
During the past 4 years, the highest EV-to-EBIT of Cyteir Therapeutics was 563.76. The lowest was -6432.96. And the median was 0.00.
CYTT's EV-to-EBIT is ranked better than 75.68% of 444
companies
in the Biotechnology industry
Industry Median: 8.05
vs CYTT: 0.55
Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Cyteir Therapeutics's Enterprise Value for the quarter that ended in Sep. 2023 was $-26.75 Mil.
Cyteir Therapeutics's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was $-38.25 Mil. Cyteir Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was 143.01%.
Cyteir Therapeutics EV-to-EBIT Historical Data
The historical data trend for Cyteir Therapeutics's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Cyteir Therapeutics's EV-to-EBIT
For the Biotechnology subindustry, Cyteir Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cyteir Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cyteir Therapeutics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Cyteir Therapeutics's EV-to-EBIT falls into.
Cyteir Therapeutics EV-to-EBIT Calculation
Cyteir Therapeutics's EV-to-EBIT for today is calculated as:
Cyteir Therapeutics's current Enterprise Value is $-20.87 Mil.
Cyteir Therapeutics's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-38.25 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Cyteir Therapeutics's Enterprise Value for the quarter that ended in Sep. 2023 was $-26.75 Mil.
Cyteir Therapeutics's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-38.25 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cyteir Therapeutics EV-to-EBIT Related Terms
Thank you for viewing the detailed overview of Cyteir Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Cyteir Therapeutics (Cyteir Therapeutics) Business Description
Cyteir Therapeutics Inc is a clinical-stage biotechnology company focused on the development of CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters. CYT-0851 is an investigational monocarboxylate transporter inhibitor or MCT inhibitor, initially evaluated in a phase 1/2 study to treat patients with hematologic malignancies and solid tumors as a monotherapy and in combination with standard-of-care therapies. Inhibiting MCT function in glycolytic cancer cells leads to an accumulation of intracellular lactate that impairs glycolysis and inhibits tumor cell growth, making MCTs an attractive target for cancer therapy.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CYTT has been successfully added to your 